6.
Faivre J, Peiffert D, Vendrely V, Lemanski C, Hannoun-Levi J, Mirabel X
. Prognostic factors of colostomy free survival in patients presenting with locally advanced anal canal carcinoma: A pooled analysis of two prospective trials (KANAL 2 and ACCORD 03). Radiother Oncol. 2018; 129(3):463-470.
DOI: 10.1016/j.radonc.2018.08.008.
View
7.
Glynne-Jones R, Sebag-Montefiore D, Adams R, Gollins S, Harrison M, Meadows H
. Prognostic factors for recurrence and survival in anal cancer: generating hypotheses from the mature outcomes of the first United Kingdom Coordinating Committee on Cancer Research Anal Cancer Trial (ACT I). Cancer. 2012; 119(4):748-55.
DOI: 10.1002/cncr.27825.
View
8.
Katz L, Horowitz D, Kachnic L
. Acute and Chronic Complications After Treatment of Locoregional Anal Cancer: Prevention and Management Strategies. J Natl Compr Canc Netw. 2023; 21(11):1204-1211.
DOI: 10.6004/jnccn.2023.7042.
View
9.
Tian D, Yan H, Huang H, Zuo Y, Liu M, Zhao J
. Machine Learning-Based Prognostic Model for Patients After Lung Transplantation. JAMA Netw Open. 2023; 6(5):e2312022.
PMC: 10163387.
DOI: 10.1001/jamanetworkopen.2023.12022.
View
10.
Shou H, Wan Q, Xu H, Shi L, Song T
. Stage IIB-IVA cervix carcinoma in elderly patients treated with radiation therapy: a longitudinal cohort study by propensity score matching analysis. BMC Womens Health. 2023; 23(1):270.
PMC: 10193738.
DOI: 10.1186/s12905-023-02427-8.
View
11.
Glynne-Jones R, Nilsson P, Aschele C, Goh V, Peiffert D, Cervantes A
. Anal cancer: ESMO-ESSO-ESTRO clinical practice guidelines for diagnosis, treatment and follow-up. Eur J Surg Oncol. 2014; 40(10):1165-76.
DOI: 10.1016/j.ejso.2014.07.030.
View
12.
Kachnic L, Winter K, Myerson R, Goodyear M, Abitbol A, Streeter O
. Long-Term Outcomes of NRG Oncology/RTOG 0529: A Phase 2 Evaluation of Dose-Painted Intensity Modulated Radiation Therapy in Combination With 5-Fluorouracil and Mitomycin-C for the Reduction of Acute Morbidity in Anal Canal Cancer. Int J Radiat Oncol Biol Phys. 2021; 112(1):146-157.
PMC: 8688291.
DOI: 10.1016/j.ijrobp.2021.08.008.
View
13.
Song T, Xu H, Shi L, Yan S
. Prognostic Analysis and Comparison of the 2014 and 2018 International Federation of Gynecology and Obstetrics Staging System on Overall Survival in Patients with Stage IIB-IVA Cervix Carcinoma. Int J Womens Health. 2022; 14:333-344.
PMC: 8909488.
DOI: 10.2147/IJWH.S348074.
View
14.
Yu W, Lu Y, Shou H, Xu H, Shi L, Geng X
. A 5-year survival status prognosis of nonmetastatic cervical cancer patients through machine learning algorithms. Cancer Med. 2022; 12(6):6867-6876.
PMC: 10067071.
DOI: 10.1002/cam4.5477.
View
15.
Pernicka J, Rauch G, Gangai N, Bates D, Ernst R, Hope T
. Imaging of Anal Squamous Cell Carcinoma: Survey Results and Expert Opinion from the Rectal and Anal Cancer Disease-Focused Panel of the Society of Abdominal Radiology. Abdom Radiol (NY). 2023; 48(9):3022-3032.
PMC: 10929685.
DOI: 10.1007/s00261-023-03863-8.
View
16.
Gardner I, Watson K
. Diagnosis and Treatment of Anal Squamous Cell Carcinoma. Dis Colon Rectum. 2020; 63(10):1358-1361.
DOI: 10.1097/DCR.0000000000001791.
View
17.
Clark M, Hartley A, Geh J
. Cancer of the anal canal. Lancet Oncol. 2004; 5(3):149-57.
DOI: 10.1016/S1470-2045(04)01410-X.
View
18.
James R, Glynne-Jones R, Meadows H, Cunningham D, Myint A, Saunders M
. Mitomycin or cisplatin chemoradiation with or without maintenance chemotherapy for treatment of squamous-cell carcinoma of the anus (ACT II): a randomised, phase 3, open-label, 2 × 2 factorial trial. Lancet Oncol. 2013; 14(6):516-24.
DOI: 10.1016/S1470-2045(13)70086-X.
View
19.
. Epidermoid anal cancer: results from the UKCCCR randomised trial of radiotherapy alone versus radiotherapy, 5-fluorouracil, and mitomycin. UKCCCR Anal Cancer Trial Working Party. UK Co-ordinating Committee on Cancer Research. Lancet. 1996; 348(9034):1049-54.
View
20.
Gordon P
. Squamous-cell carcinoma of the anal canal. Surg Clin North Am. 1988; 68(6):1391-9.
DOI: 10.1016/s0039-6109(16)44694-3.
View